이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

관절 건강에 대한 Elocta의 장기적 효과를 평가하기 위한 48개월 연구 (A-MORE)

2026년 9월 18일 업데이트: Swedish Orphan Biovitrum

관절 건강에 대한 Elocta의 장기적 효과를 평가하기 위한 48개월, 다기관, 관찰 연구

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

연구 유형

관찰

등록 (실제)

427

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Thessaloniki, 그리스
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, 그리스
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Groningen, 네덜란드
        • University Medical Center Groningen/UMCG
      • Berlin, 독일
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, 독일
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, 독일
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, 독일
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, 독일
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, 독일
        • Medizinische Hochschule Hannover
      • Hanover, 독일
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, 독일
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, 독일
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, 독일
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Riyadh, 사우디 아라비아
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, 사우디 아라비아
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, 사우디 아라비아
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, 사우디 아라비아
        • Riyadh Military Hospital (P.S.M.C)
      • Gothenburg, 스웨덴
        • Hematologimottagning Sahlgrenska
      • Malmö, 스웨덴
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern, 스위스
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, 스위스
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, 스위스
        • Zentrum für Labormedizin
      • Zurich, 스위스
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Barcelona, 스페인
        • Sant Johan De Deu
      • Barcelona, 스페인
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, 스페인
        • Hospital Vall d'Hebron
      • Cruces, 스페인
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, 스페인
        • Hospital Universitario Donostia
      • Murcia, 스페인
        • Hospital Virgen de la Arrixaca
      • Málaga, 스페인
        • Hospital Universitario Carlos Haya
      • Navarro, 스페인
        • Complejo Hospitalario de Navarra
      • Oviedo, 스페인
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, 스페인
        • Hospital Universitario Son Espases
      • Seville, 스페인
        • Hospital Universitario Virgen del Rocío
      • Vigo, 스페인
        • Hospital Alvaro Cunqueiro
      • Ljubljana, 슬로베니아
        • University Medical Centre Ljubljana Division of Paediatrics
      • Tallinn, 에스토니아
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, 에스토니아
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Canterbury, 영국
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, 영국
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Muscat, 오만
        • The Royal Hospital
      • Bari, 이탈리아
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, 이탈리아
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, 이탈리아
        • Giannina Gaslini Institute
      • Milan, 이탈리아
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, 이탈리아
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, 이탈리아
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, 이탈리아
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Brno, 체코
        • University Hospital Brno
      • Ostrava, 체코
        • University Hospital Ostrava
      • Prague, 체코
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Helsinki, 핀란드
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, 핀란드
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

설명

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

다른 이름들:
  • efmoroctocog 알파
  • ELOCTATE
  • rFVIIIFc

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Joint health: Target joint development
기간: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
기간: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
기간: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
기간: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

2차 결과 측정

결과 측정
측정값 설명
기간
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
기간: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
기간: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
기간: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

기타 결과 측정

결과 측정
측정값 설명
기간
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
기간: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
기간: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
기간: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
기간: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
기간: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
기간: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
기간: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
기간: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
기간: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
기간: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
기간: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
기간: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
기간: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
기간: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
기간: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
기간: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
기간: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
기간: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
기간: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
기간: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
기간: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Study Physician, Swedish Orphan Biovitrum

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 3월 30일

기본 완료 (실제)

2026년 5월 4일

연구 완료 (실제)

2026년 5월 4일

연구 등록 날짜

최초 제출

2020년 2월 20일

QC 기준을 충족하는 최초 제출

2020년 3월 2일

처음 게시됨 (실제)

2020년 3월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 18일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다